RxDoctor Payments DataLook up a doctor →

Stephen Chen, MD

Critical Care Medicine · Monterey Park, CANPI 1205821477

Payments from drug & device makers

$393,623in general payments, 2019–2025

Across 832 payments — averaging $473.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$216K
  • AstraZeneca$105K
  • Boehringer Ingelheim$29K
  • Mylan Specialty L.p.$12K
  • Bayer$11K
  • AbbVie$10K
  • plus $10K from 33 others

What the payments were for

  • Consulting fees$12,3793%
  • Speaking & faculty fees$348,51089%
  • Travel & lodging$6,5592%
  • Food & beverage$25,3836%
  • Education$7930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$393,623 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$735,438
Medicare patients
1,219
Services billed
5,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter563$395,265
AdempasRiociguat28$390,397
OfevNintedanib Esylate28$352,104
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr258$133,876
Breztri AerosphereBudesonide/Glycopyr/Formoterol186$127,155
Ambrisentan24$119,256
Fasenra PenBenralizumab17$92,963
Breo ElliptaFluticasone/Vilanterol174$77,615
CreonLipase/Protease/Amylase65$75,131
Combivent RespimatIpratropium/Albuterol Sulfate150$74,589
JardianceEmpagliflozin83$54,815
NucalaMepolizumab13$47,981
Stiolto RespimatTiotropium Br/Olodaterol Hcl84$43,682
Roflumilast339$42,339
EliquisApixaban49$30,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta$216,453$672,7821,050 claims
Boehringer IngelheimOfev, Combivent Respimat, Jardiance, Stiolto Respimat, Spiriva Respimat$28,968$549,302379 claims
BayerAdempas$11,225$390,39728 claims
AstraZenecaBreztri Aerosphere, Farxiga$105,032$135,339201 claims
AbbVieCreon, Restasis, Linzess, Lumigan$9,971$110,769131 claims
PfizerEliquis$14$30,41149 claims
MerckJanuvia, Belsomra$999$19,96739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Monterey Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →